Verrica Pharmaceuticals Inc.
VRCA
$0.4891
$0.02264.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 34.18% | 7.83% | -56.38% | -208.56% | -314.94% |
| Total Depreciation and Amortization | 16.59% | 62.86% | 61.35% | 68.32% | 7.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.84% | -70.78% | 86.85% | 133.55% | 321.04% |
| Change in Net Operating Assets | -184.06% | 4,021.71% | -152.32% | -457.18% | 1,269.95% |
| Cash from Operations | -10.73% | 42.22% | -250.35% | -334.58% | -192.83% |
| Capital Expenditure | 100.00% | 75.38% | 81.36% | -- | -243.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 103.52% | 75.38% | 81.36% | -- | -103.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,526.09% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -99.99% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5,500.00% | -195.08% | -629.76% | -1,717.86% | -- |
| Cash from Financing | 146,122.22% | -100.90% | -661.90% | -102.18% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 258.32% | -130.76% | -253.47% | -180.25% | -920.06% |